Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
A major impediment to the use of adeno-associated virus (AAV)-mediated gene delivery to muscle in clinical applications is the pre-existing immune responses against the vector. Pre-existing humoral response to different AAV serotypes is now well documented. In contrast, cellular responses to AAV capsid have not been analyzed in a systematic manner, despite the risk of T cell reactivation upon gene transfer. AAV1 has been widely used in humans to target muscle. In this study, we analyzed PBMCs and sera of healthy donors for the presence of AAV1 capsid-specific T cell responses and AAV1 neutralizing factors. Approximately 30% of donors presented AAV1 capsid-specific T cells, mainly effector memory CD8+ cells. IFN-γ–producing cells were also observed among effector memory CD4+ cells for two of these donors. Moreover, to our knowledge, this study shows for the first time on a large cohort that there was no correlation between AAV1-specific T cell and humoral responses. Indeed, most donors presenting specific Ig and neutralizing factors were negative for cellular response (and vice versa). These new data raise the question of prescreening patients not only for the humoral response, but also for the cellular response. Clearly, a better understanding of the natural immunology of AAV serotypes will allow us to improve AAV gene therapy and make it an efficient treatment for genetic disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies characterized T-cell responses in healthy human subjects and reported 10–100% of human subjects have functional circulating capsid-specific T cells against multiple AAV serotypes [109–111].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [110]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“Furthermore, it has been shown that the host immune response to the AAV capsid mediated by circulating Abs may prevent repeated administrations (9).”
BackgroundXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“Briefly, HEK293 cells were tritransfected with the adenovirus helper plasmid pXX6 (22), a pAAV packaging plasmid expressing the rep and cap genes pLT-RC02 for AAV1 (23) and the relevant pAAV2 vector plasmid.”
MethodClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 2×
“80% homology at the nucleotide level, suggesting cross-reactions between them (18).”
BackgroundKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 12×
“Briefly, CD3, CD4, CD8, CD45RA, CD62L, and CD25 Abs were diluted in PBS with 3% FCS at recommended concentrations and were added to the cells for 30 min at 4˚C in the dark.”
BackgroundMethodResultSelf-citationWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 2×
“(8), which was consistent with another report concerning Europe (7).”
ResultAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 17×
“The frequency of circulating capsid-specific T cells was determined by IFN-g ELISPOT in which cells were stimulated with AAV-specific overlapping peptides (12, 16).”
BackgroundMethodInfluentialMoss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D., Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., et al. (2004) · Chest · doi:10.1378/chest.125.2.509 · Cited by 390
Flotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327
Adeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323 · cited 1×
“Despite the fact that AAV2 has been isolated from humans and AAV1 and AAV8 from nonhuman primates (17, 18), pre-existing immune responses have been observed in humans against these different serotypes, which share .”
BackgroundMingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Mendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
Snyder, R. O., Spratt, S. K., Lagarde, C., Bohl, D., Kaspar, B., Sloan, B., Cohen, L. K., & Danos, O. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.16-1891 · Cited by 211 · cited 1×
“Single-stranded AAV vectors were produced with conventional pGG2 AAV2 vector plasmid expressing luciferase (24) under the transcriptional control of the CMV immediate early promoter associated with the SV40 poly(A) signal.”
MethodStroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · cited 2×
“The neutralizing assay was performed as previously described, with some modifications (27).”
MethodSelf-citationEbenbichler, C. F., Thielens, N. M., Vornhagen, R., Marschang, P., Arlaud, G. J., & Dierich, M. P. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.6.1417 · Cited by 202
Rivière, C., Danos, O., & Douar, A. M. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302766 · Cited by 192 · cited 1×
“Briefly, HEK293 cells were tritransfected with the adenovirus helper plasmid pXX6 (22), a pAAV packaging plasmid expressing the rep and cap genes pLT-RC02 for AAV1 (23) and the relevant pAAV2 vector plasmid.”
MethodCD3+CD4−CD8− (double negative) T cells: Saviours or villains of the immune response?
D’Acquisto, F., & Crompton, T. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.019 · Cited by 172 · cited 1×
“In our study, we also observed AAV1 capsid-specific CD3 double-negative CD4(2)CD8(2) cells, which have not yet been systematically analyzed (28) and are described FIGURE 5.”
BackgroundHarris, S. L., Frank, I., Vee, A., Cohen, G. H., Eisenberg, R. J., & Friedman, H. M. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/162.2.331 · Cited by 134
Diverse IgG subclass responses to adeno‐associated virus infection and vector administration
Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A., & High, K. A. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21360 · Cited by 101 · cited 1×
“As previously described for AAV2 (6), we recently showed that natural exposure to AAV types 1, 2, 5, 6, 8, and 9 can result in production of Abs from all four IgG subclasses, with a predominant IgG1 response.”
Herson, S., Hentati, F., Rigolet, A., Béhin, A., Romero, N. B., Leturcq, F., Laforêt, P., Maisonobe, T., Amouri, R., Haddad, H., et al. (2011) · Brain · doi:10.1093/brain/awr342 · Cited by 99
Self-citationCharrier, S., Dupré, L., Scaramuzza, S., Jeanson-Leh, L., Blundell, M. P., Danos, O., Cattaneo, F., Aiuti, A., Eckenberg, R., Thrasher, A. J., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302863 · Cited by 91 · cited 2×
“Vectors were titered as infectious genomes (IG) per milliliter on HCT116 cells using quantitative PCR as previously described (25), and vector particle was measured by HIV-1 gag p24 Ag immunocapture (PerkinElmer, Waltham, MA) and expressed in ng p24/ml.”
MethodLi, H., Lasaro, M. O., Jia, B., Lin, S. W., Haut, L. H., High, K. A., & Ertl, H. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.81 · Cited by 83 · cited 18×
“The frequency of circulating capsid-specific T cells was determined by IFN-g ELISPOT in which cells were stimulated with AAV-specific overlapping peptides (12, 16).”
BackgroundMethodResultInfluentialLevy, J. A., Ihle, J. N., Oleszko, O., & Barnes, R. D. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.12.5071 · Cited by 67
Neutralization of Epstein-Barr Virus by Nonimmune Human Serum
Nemerow, G. R., Jensen, F. C., & Cooper, N. R. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110696 · Cited by 39
(2007) · Molecular Therapy · doi:10.1016/s1525-0016(16)45262-7 · Cited by 5
Research works printed but not linked: 2
- Nierman, 2007, Safety and efficacy of AMT-010, an adeno-associated virus based gene therapy vector administered to lipoprotein lipase-deficient subjects, Hum. Gene Ther., 18, 942
- Mingozzi, 2007, Capsid-specific T cell responses in humans upon intramuscular administration of an AAV-1 vector expressing LPLs447X transgene, Hum. Gene Ther., 18, 94
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“One key concept to keep in mind when studying immune responses to AAV vectors is that the viral capsid is identical or nearly identical to the capsid of the wild-type virus, to which humans are exposed.(4,61,62) Thus, it is expected that the host immune responses”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“The prevalence of T cells directed against AAV1 and AAV2 in the general population has been investigated through a variety of functional assays, which include enzyme-linked immunospot (ELISPOT) and flow cytometry-based assays.(42,45,47) Although the prevalence can vary across studies, depending on the sensitivity of t…”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“This may explain why different independent studies reported a lack of correlation between preexisting cellular and humoral immune responses (50, 56, 58).”
BackgroundMethodInfluentialPre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
“In most of these studies, there was a significant—but not perfect—correlation between the anti-AAV immunoglobulin titers determined by ELISA and the neutralizing titers (Chirmule et al., 1999; Erles et al., 1999; Murphy et al., 2009; Boutin et al., 2010; Veron et al., 2012).”
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citation
Metadata
- Authors
- Veron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C.
- Affiliations
- Genethon (France) (FR)
- Inserm (FR)
- Corresponding author
- Veron, Philippe
- Leborgne, Christian
- Monteilhet, Virginie
- Boutin, Sylvie
- Moullier, Philippe
- Masurier, Carole
- ORCID
- Leborgne, Christian
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06
- Volume
- 188
- Issue
- 12
- Pages
- 6418-6424
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2170549121
- Cited by
- 88
- References
- 30
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 6 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 9 · 2016: 4 · 2015: 8 · 2014: 3 · 2013: 9 · 2012: 1
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus type 1, humoral immune response, neutralizing antibodies, CD8+ effector memory T cells, CD4+ T cells, interferon-gamma, AAV serotypes, gene therapy safety, healthy donors
- MeSH terms
- Dependovirus, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Genetic Vectors, Humans, Immunity, Cellular, Immunologic Memory, Random Allocation, T-Lymphocytes, Genetic Therapy, Capsid Proteins, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.